Safety and Efficacy of YB-1113 in Treatment of POI
This phase 1 study is to evaluate the safety and tolerability of YB-1113 administered via intravenous (IV) infusion in the treatment of premature ovarian insufficiency (POI).
Female, 18 to <40 years old, who are seeking fertility or preservation of fertil... [+5]
1. Primary amenorrhea or FSH ≥ 40 IU/L [+16]